Efficacy comparison with low and high dose nadroparin for patients with acute coronary syndrome underwent percutaneous coronary intervention / 中华心血管病杂志
Chinese Journal of Cardiology
;
(12): 493-496, 2008.
Article
in Chinese
| WPRIM
| ID: wpr-243747
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the safety and optimal prior percutaneous coronary intervention (PCI) nadroparin dose in patients with acute coronary syndrome (ACS).</p><p><b>METHODS</b>A total of 236 ACS patients were randomly treated with subcutaneously nadroparin 0.075 ml/10 kg (group I, n = 120) and 0.1 ml/10 kg (group II, n = 116) respectively (bid for 48 hours). PCI was the performed 1 h after final nadroparin injection. No additional nadroparin was applied during PCI. Plasmic anti-Xa level was assayed before and at 1, 2, 4 and 8 hours after final nadroparin administration. Adverse clinical events (death, myocardial infarction, need for revascularization) and bleeding events were recorded up to 30 days post PCI.</p><p><b>RESULTS</b>Baseline clinical characteristics as well as the MACE and severe bleeding events between the two groups were similar (all P > 0.05). Plasmic anti-Xa level of group II was significantly higher than that of group I post nadroparin application (P < 0.01).</p><p><b>CONCLUSION</b>Anticoagulation effects and MACE as well as severe bleeding events up to 30 days post PCI were similar with either 0.075 ml/10 kg or 0.1 ml/10 kg nadroparin dose in ACS patients.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Angioplasty, Balloon, Coronary
/
Thrombolytic Therapy
/
Nadroparin
/
Drug Therapy
/
Acute Coronary Syndrome
/
Methods
/
Anticoagulants
Limits:
Aged
/
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Chinese Journal of Cardiology
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS